Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Industrials, Basic Materials and Technology sectors led shares lower. At the close in NYSE,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Neutral | Sell |
| Technical Indicators | Buy | Buy | Neutral | Neutral | Sell |
| Summary | Strong Buy | Strong Buy | Buy | Neutral | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | NASDAQ | |||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | NASDAQ | |||
| 9.98 | 9.98 | 9.96 | +0.010 | +0.10% | 53.52K | NASDAQ | |||
| 75.94 | 76.04 | 74.89 | +0.41 | +0.54% | 12.35M | NASDAQ | |||
| 3.20 | 3.39 | 3.13 | -0.040 | -1.23% | 14.27K | NASDAQ | |||
| 4.64 | 4.857 | 4.415 | +0.040 | +0.87% | 49.72K | NASDAQ | |||
| 124.62 | 130.73 | 116.16 | -10.06 | -7.47% | 8.68M | NASDAQ | |||
| 36.81 | 36.87 | 36.27 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 7.00 | 7.10 | 6.39 | 0.00 | 0.00% | 13.60K | NASDAQ | |||
| 42.52 | 43.38 | 42.48 | -0.13 | -0.30% | 291.17K | NYSE | |||
| 0.7299 | 0.00 | 0.00 | -0.0801 | -9.89% | 1.73M | NASDAQ | |||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | NASDAQ | |||
| 46.51 | 47.20 | 46.12 | +0.60 | +1.31% | 5.03M | NYSE | |||
| 57.01 | 57.33 | 56.45 | +0.54 | +0.96% | 12.14M | NYSE | |||
| 55.34 | 56.28 | 54.73 | -0.90 | -1.60% | 10.62M | NYSE |
BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.